HuidaGene Receives Orphan Drug Designation for Gene Therapy of Blindness

HuidaGene Therapeutics (辉大基因; HuidaGene) announces that the US. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for HG004, HuidaGene’s lead gene replacement therapy for the treatment of inherited retinal disease caused by RPE65 mutations.